Development of Iceleusin for the CTD-ILD indication
A development program for アイ スーリュイ (pirfenidone) aimed at expanding its indications through a Phase 3 clinical trial in scleroderma and dermatomyositis associated with connective tissue disease-related interstitial lung disease (CTD-ILD).
Companies1How many companies write about this.
Threads2One company can carry more than one thread here.